The report includes data on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Industries Direct’s proprietary databases, Alnylam Pharmaceuticals, Inc’s corporate website, SEC filings, investor presentations and featured press releases, both from Alnylam Pharmaceuticals, Inc and market -specific third party sources, put together by Global Industries Direct’s team.
Scope of the Research
- Alnylam Pharmaceuticals, Inc - Brief Alnylam Pharmaceuticals, Inc overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Alnylam Pharmaceuticals, Inc human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Alnylam Pharmaceuticals, Inc with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Alnylam Pharmaceuticals, Inc’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Why Should You Get This Report?
- Evaluate Alnylam Pharmaceuticals, Inc’s strategic position with total access to detailed data on its product pipeline.
- Assess the growth opportunities of Alnylam Pharmaceuticals, Inc in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Alnylam Pharmaceuticals, Inc’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Alnylam Pharmaceuticals, Inc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Alnylam Pharmaceuticals, Inc and identify potential opportunities in those areas.
Drug Discovery And Development Industry in the United States
Table of Contents
Data table of Contents 2
List of Tables 7
List of Figures 10
Alnylam Pharmaceuticals, Inc Snapshot 11
Alnylam Pharmaceuticals, Inc Overview 11
Key Information 11
Key Facts 11
Alnylam Pharmaceuticals, Inc – Research and Development Overview 12
Key Therapeutic Areas 12
Alnylam Pharmaceuticals, Inc – Pipeline Review 15
Pipeline Products by Stage of Development 15
Alnylam Pharmaceuticals, Inc – Pipeline Products Glance 16
Alnylam Pharmaceuticals, Inc – Late Stage Pipeline 16
Registration Filed Products/Combination Treatment Modalities 16
Alnylam Pharmaceuticals, Inc Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
Alnylam Pharmaceuticals, Inc–Early Stage Pipeline Products 19
Pre-Clinical Products/Combination Treatment Modalities 19
Discovery Products/Combination Treatment Modalities 20
Alnylam Pharmaceuticals, Inc – Drug Profiles 21
Actos + Glimepiride 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
ALN-HPN 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
ALN-HTT 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
ALN-PCS 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
ALN-RSV01 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ALN-TTR01 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ALN-TTR02 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ALN-VSP 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Drug For Dystonia 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Drug For Malaria 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
JC Virus Programe 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Pandemic Flu Programme 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Parkinson's disease development Program 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
RNAi Therapeutic 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
RNAi Therapeutics Program 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Alnylam Pharmaceuticals, Inc – Pipeline Analysis 37
Alnylam Pharmaceuticals, Inc – Pipeline Products by Therapeutic Class 37
Alnylam Pharmaceuticals, Inc - Pipeline Products By Target 39
Alnylam Pharmaceuticals, Inc – Pipeline Products by Route of Administration 41
Alnylam Pharmaceuticals, Inc – Pipeline Products by Molecule Type 42
Alnylam Pharmaceuticals, Inc – Recent Pipeline Updates 43
Alnylam Pharmaceuticals, Inc - Dormant Projects 46
Alnylam Pharmaceuticals, Inc – Firms Statement 47
Alnylam Pharmaceuticals, Inc – Operations and Subsidiaries 50
Head Office 50
Other Locations & Subsidiaries 50
Recent Developments 51
March 31, 2011: Alnylam Completes Enrollment In ALN-VSP Phase I Clinical Trial 51
March 31, 2008: Alnylam Presents Pre-clinical Data from Hypercholesterolemia, Liver Cancer, Ebola, And Progressive Multifocal Leukoencephalopathy (PML) Programs At RNAi Keystone Symposium 51
March 31, 2008: Alnylam Presents Pre-clinical Data From Hypercholesterolemia, Liver Cancer, Ebola, And Progressive Multifocal Leukoencephalopathy (PML) Programs At RNAi Keystone Symposium. 52
July 30, 2007: Alnylam And Medtronic Advance Collaboration On Drug-Device Combinations with RNAi Therapeutics For CNS Diseases 53
September 29, 2010: Alnylam Announces Publication Of Phase IIa Study Results Of ALN-RSV01 In Treatment Of RSV Infection In Lung Transplant Patients 54
June 29, 2010: Alnylam Obtains Approval To Initiate Phase I Study With ALN-TTR01 In Patients With TTR-Mediated Amyloidosis 55
June 28, 2011: Alnylam Presents New Data From ALN-TTR Program At Peripheral Nerve Society Meeting 55
April 27, 2010: Alnylam Publishes Results From Phase II GEMINI Trial With ALN-RSV01 57
September 26, 2011: Alnylam Initiates Phase I Clinical Study Of ALN-PCS In Hypercholesterolemia 57
January 25, 2011: Alnylam Receives Positive Opinion For Orphan Drug Designation From European Medicines Agency For ALN-TTR01 58
December 23, 2008: Alnylam Advances RNAi Therapeutics Pipeline And Files Firms 's First Systemic Delivery IND. 59
October 23, 2006: Alnylam Announces Progress In Pre-Clinical Hypercholesterolemia RNAi Therapeutic And MicroRNA Programs 60
May 23, 2006: Alnylam And Collaborators Present Pre-Clinical Data For RNAi Therapeutics For The Treatment Of Respiratory Diseases 61
May 23, 2006: Alnylam and Collaborators Present Pre-Clinical Data For RNAi Therapeutics For The Treatment Of Respiratory Diseases Including Pandemic Influenza 62
January 23, 2009: Alnylam Receives Clearance From FDA To Initiate Phase I Study With ALN-VSP For The Treatment Of Liver Cancers. 63
February 22, 2010: Alnylam Initiates Phase IIb Clinical Trial Of ALN-RSV01 In Adult Lung Transplant Patients Infected with RSV Infection 64
January 21, 2009: Alnylam And Collaborators At Harvard Medical School Demonstrate In Vivo Silencing Of Key Genes Implicated In The Transmission Of Herpes Simplex Virus-2 (HSV-2) 65
November 20, 2008: Alnylam Presents Pre-clinical Data From TTR Amyloidosis Development Program 66
November 20, 2008: Alnylam Presents Pre-clinical Data From TTR Amyloidosis Development Program 20th November 2008 67
July 20, 2009: Alnylam And Cubist Reports Complete Data From Phase II Study In Respiratory Syncytial Virus 68
April 20, 2010: Alnylam And Collaborators Present New Pre-Clinical Data From ALN-TTR01 Program 68
June 19, 2008: Alnylam And Kyowa Hakko Form Alliance For The Development And Commercialization Of ALN-RSV01 In Asia 70
June 18, 2009: Alnylam And Collaborators Presents New Pre-Clinical Research Findings On RNAi Therapeutics Targeting PCSK9 71
May 18, 2011: Alnylam's ALN-VSP Abstract Published By American Society Of Clinical Oncology 72
March 18, 2005: In Vivo Efficacy Data Presented From Alnylam RSV Program At The American Academy Of Allergy, Asthma And Immunology Meeting 73
September 15, 2009: Alnylam And Medtronic Presents New Late-Stage Pre-clinical Data On ALN-HTT For The Treatment Of Huntington's Disease. 74
August 15, 2005: Alnylam Receives Grant From Michael J. Fox Foundation For Parkinson's Research To Support The Development Of November el Parkinson's Therapies Using RNAi Technology 75
December 14, 2005: Alnylam Announces Pandemic Flu As Next Development Program; Obtains Initial Federal Funding to Develop RNAi Therapeutics For Pandemic Influenza And Identifies Dowpharma(SM) As Potential Source For Domestic Manufacturing. 76
December 13, 2007: Alnylam Reports Phase I Clinical Safety Results With Inhalation Dosing Of ALN-RSV01 76
August 12, 2008: Alnylam And Collaborators Publish New Pre-Clinical Research On RNAi-Mediated Silencing Of PCSK9 78
October 11, 2006: Alnylam Initiates Phase I Clinical Study Of Inhaled Formulation Of ALN-RSV01 79
July 11, 2011: Alnylam Files Clinical Trial Application For ALN-PCS For Treatment Of Severe Hypercholesterolemia 80
January 11, 2008: Nucleonics Initiates Hepatitis B Clinical Trial with Expressed Interfering RNA Therapeutic, NUCB1000 81
November 10, 2010: Alnylam Presents Additional Interim Phase I Data For ALN-VSP For Treatment Of Liver Cancer 81
April 09, 2008: Alnylam Initiates Phase II Trial Of ALN-RSV01 In Adult Lung Transplant Patients Naturally Infected With Respiratory Syncytial Virus (RSV) Infection 83
February 09, 2005: Medtronic And Alnylam Pharmaceuticals To Collaborate On Potential Treatments For Major Neurodegenerative Diseases 84
September 08, 2011: Alnylam Expands Alnylam 5x15 RNAi Therapeutic Pipeline With ALN-APC, RNAi Therapeutic Targeting Protein C For Treatment Of Hemophilia 85
June 08, 2009: Alnylam And Cubist Report Preliminary Data From Phase II Study Of ALN-RSV01 86
July 07, 2010: Alnylam Doses ATTR Patients In Phase I Clinical Study Of ALN-TTR01 87
June 07, 2010: Alnylam Presents Preliminary Phase I Data At ASCO Meeting For ALN-VSP 88
November 06, 2006: Alnylam And Yale University Scientists Demonstrate Therapeutic Silencing Of Disease Target Associated With Acute Lung Injury Using RNAi 89
August 06, 2008: Tekmira Pharmaceuticals Provides Progress Update On Alnylam's ALN-VSP. 90
June 04, 2011: Alnylam Presents Phase I Data For ALN-VSP At American Society Of Clinical Oncology Meeting 91
January 04, 2011: Alnylam Reports Positive Data From ALN-VSP Phase I Liver Cancer Trial 93
April 03, 2009: Alnylam Initiates Phase I Clinical Study of ALN-VSP in Patients with Liver Cancer 94
November 02, 2009: Alnylam Presents New Pre-Clinical Data ALN-TTR, RNAi Therapeutic Treatment Transthyretin-Mediated Amyloidosis 95
November 02, 2009: Alnylam Presents New Pre-Clinical Data ALN-TTR, RNAi Therapeutic Treatment Transthyretin-Mediated Amyloidosis 96
November 01, 2005: Alnylam Submits IND Application For ALN-RSV01 97
August 01, 2011: Alnylam Completes Phase I Trial Of ALN-VSP In Liver Cancer 98
Financial Deals Landscape 99
Alnylam Pharmaceuticals, Inc, Merger and Acquisition Deal Summary 99
Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Merger and Acquisition Deal Details 105
Asset Transactions 105
Alnylam Takes Over RNAi Therapeutics Assets From Nucleonics 105
Venture Financing 107
Regulus Therapeutics Secures US$ 20 Mln In Series A Preferred Equity Financing 107
Partnerships 109
Molecular Templates Enters Into Research Collaboration With Alnylam Pharmaceuticals 109
Precision NanoSystems Enters Into Delivery Collaboration With Alnylam 110
AlCana Extends Co-Development Agreement With UBC And Alnylam 111
Alnylam And Medtronic Form Collaboration With CHDI Foundation 113
Alnylam Pharmaceuticals Enters Into Agreement With Tekmira Pharmaceuticals 115
November artis Extends Agreement With Alnylam Pharmaceuticals 116
Cubist Pharmaceuticals Enters Into Co-Development Agreement With Alnylam 117
Alnylam Enters Into Research Agreement With Max Planck Institute 119
November artis Extends Co-Development Agreement With Alnylam Pharmaceuticals 120
Alnylam Pharmaceuticals And Kyowa Hakko Form Alliance 121
Alnylam Pharmaceuticals Forms Joint Venture With Isis Pharmaceuticals 122
Alnylam Pharmaceuticals Amends Agreement With Medtronic 123
Biogen Idec Enters Into Agreement With Alnylam 124
Tekmira Amends Research Collaboration With Alnylam Pharmaceuticals 125
Alnylam Pharmaceuticals Amends Its Collaboration Agreement With Merck 126
Alnylam Pharmaceuticals Enters Into Collaboration Agreement With USAMRIID 128
Alnylam Pharmaceuticals Enters Into Research Agreement With Inex Pharmaceuticals 129
Alnylam Enters Into Co-Development Agreement With November artis 130
Alnylam Enters Into Agreement With November artis 131
Alnylam Pharmaceuticals Enters Into Collaboration With University Of Georgia 133
Alnylam Enters Into Agreement With Cystic Fibrosis Foundation 134
Alnylam Enters Into Agreement With Medtronic 135
Merck Concludes a New Deal With Alnylam Pharmaceuticals 136
Alnylam Enters Into Agreement With Cenix Bioscience 137
Licensing Agreements 138
Bio-Rad Laboratories Concludes a New Deal With Alnylam Pharmaceuticals 138
Alnylam Pharmaceuticals Enters Into Licensing Agreement With Inex Pharmaceuticals 139
Alnylam Enters Into Licensing Agreement With Dharmacon 140
Alnylam Enters Into License Agreement With Hybridon 141
Alnylam Pharmaceuticals Enters Into Licensing Agreement With GlaxoSmithKline 142
Tekmira Pharmaceuticals Enters Into Licensing Agreement With Alnylam Pharmaceuticals 143
Alnylam Pharmaceuticals Enters Into Licensing Agreement With Tekmira Pharmaceutical 144
The University of Queensland Enters Into Licensing Agreement With Alnylam Pharmaceuticals 145
Alnylam Pharmaceuticals Enters Into Licensing Agreement With Mount Sinai School 146
Alnylam Pharmaceuticals Enters Into Licensing Agreement With University of Queensland 147
Roche Expands Licensing Agreement With Alnylam 148
Alnylam Enters Into License Agreement With Koken 149
Alnylam Pharmaceuticals Enters Into Licensing Agreement With Isis Pharmaceuticals 150
Alnylam Pharmaceuticals Enters Into Licensing Agreement With Calando Pharmaceuticals 151
Takeda Pharmaceutical Enters Into Collaboration Agreement With Alnylam Pharmaceuticals 152
Alnylam Pharmaceuticals And Tekmira Pharmaceutical Enter Into Licensing Agreement 154
Alnylam Enters Into Agreement With Shanghai GenePharma 155
Alnylam Pharmaceuticals Enter Into Licensing Agreement With GeneDesign 156
Roche Enters Into Licensing Agreement With Alnylam Pharmaceuticals 157
Alnylam Pharmaceuticals Enters Into Licensing Agreement with Hayashi Kasei 159
Alnylam Enters Into Licensing Agreement With Inex Pharmaceuticals 160
Alnylam Pharmaceuticals Enters Into Licensing Agreement With Quark Pharmaceuticals 161
Alnylam Enters Into Agreement With Calando 162
Alnylam Enters Into Agreement With Bioneer 163
Alnylam Enters Into Agreement With Immune Disease Institute 164
Alnylam Enters Into Agreements With Massachusetts Institute of Technology 165
Gen-Probe Enters Into Licensing Agreement With Alnylam Pharmaceuticals 166
Alnylam Pharmaceuticals Enters Into Licensing Agreement With Integrated DNA Technologies 167
Alnylam Pharmaceuticals Enters Into Licensing Agreement With QIAGEN 168
Alnylam And Isis Enter Into License Agreement With Stanford University 169
Alnylam Enters Into License Agreement With MWG Biotech 170
Nastech Pharmaceutical Enters Into Agreement With Alnylam Pharmaceuticals 171
Alnylam Enters Into A Licensing Agreement With Sigma-Aldrich 172
Alnylam Enters Into License Agreement With Eurogentec 173
Alnylam Amends Its Agreements With Max Planck Society 174
Alnylam Enters Into Agreement With Ambion 175
Alnylam Enters Into Agreement With Benitec 176
Alnylam Pharmaceuticals Enters Into Licensing Agreement With GeneCare Research Institute 177
Alnylam And Isis Enter Into Licensing Agreement With Max Planck Society 178
Isis Pharmaceuticals Enters Into Licensing Agreement With Alnylam Pharmaceuticals 179
Alnylam Enters Into License Agreement With RNAX 180
Alnylam Enters Into Licensing Agreement With Invitrogen 181
Alnylam Enters Into Licensing Agreement With Cell Signaling Technology 182
Equity Offering 183
Alnylam Pharmaceuticals Files Registration Statement For Public Offering Of Securities For US$ 150 Mln 183
Alnylam Completes Private Placement Of US$ 1 Mln With November artis 184
Tekmira Completes Private Placement Of US$ 5 Mln With Alnylam 186
Alnylam Pharmaceuticals Completes Private Placement Of US$ 5 Mln 188
Alnylam Pharmaceuticals Completes Public Offering Of US$ 103 Mln 190
Alnylam Completes Public Offering Of US$ 67 Mln 192
Alnylam Pharmaceuticals Completes Private Placement Of US$ 5 Mln 194
Alnylam Pharmaceuticals Completes Initial Public Offering Of US$ 35 Mln 196
Appendix 198
Methodology 198
Coverage 198
Secondary Research 198
Primary Research 198
Expert Panel Validation 199
Contact Us 199
Disclaimer 199
List of Tables
Alnylam Pharmaceuticals, Inc – Pipeline by Therapy Area and Indication, H2 2011 14
Alnylam Pharmaceuticals, Inc – Pipeline by Stage of Development, H2 2011 15
Alnylam Pharmaceuticals, Inc – Filed, H2 2011 16
Alnylam Pharmaceuticals, Inc - Phase II, H2 2011 17
Alnylam Pharmaceuticals, Inc - Phase I, H2 2011 18
Alnylam Pharmaceuticals, Inc - Pipeline By Therapeutic Class, H2 2011 38
Alnylam Pharmaceuticals, Inc - Pipeline By Target, H2 2011 40
Alnylam Pharmaceuticals, Inc – Pipeline By Route of Administration, H2 2011 41
Alnylam Pharmaceuticals, Inc – Pipeline By Molecule Type, H2 2011 42
Alnylam Pharmaceuticals, Inc – Recent Pipeline Updates, H2 2011 43
Alnylam Pharmaceuticals, Inc - Dormant Developmental Projects, 2010 46
Alnylam Pharmaceuticals, Inc, Subsidiaries 50
Alnylam Pharmaceuticals, Inc, Merger and Acquisition Deal Summary 99
Alnylam Takes Over RNAi Therapeutics Assets From Nucleonics 105
Regulus Therapeutics Secures US$ 20 Mln In Series A Preferred Equity Financing 107
Molecular Templates Enters Into Research Collaboration With Alnylam Pharmaceuticals 109
Precision NanoSystems Enters Into Delivery Collaboration With Alnylam 110
AlCana Extends Co-Development Agreement With UBC And Alnylam 111
Alnylam And Medtronic Form Collaboration With CHDI Foundation 113
Alnylam Pharmaceuticals Enters Into Agreement With Tekmira Pharmaceuticals 115
November artis Extends Agreement With Alnylam Pharmaceuticals 116
Cubist Pharmaceuticals Enters Into Co-Development Agreement With Alnylam 117
Alnylam Enters Into Research Agreement With Max Planck Institute 119
November artis Extends Co-Development Agreement With Alnylam Pharmaceuticals 120
Alnylam Pharmaceuticals And Kyowa Hakko Form Alliance 121
Alnylam Pharmaceuticals Forms Joint Venture With Isis Pharmaceuticals 122
Alnylam Pharmaceuticals Amends Agreement With Medtronic 123
Biogen Idec Enters Into Agreement With Alnylam 124
Tekmira Amends Research Collaboration With Alnylam Pharmaceuticals 125
Alnylam Pharmaceuticals Amends Its Collaboration Agreement With Merck 126
Alnylam Pharmaceuticals Enters Into Collaboration Agreement With USAMRIID 128
Alnylam Pharmaceuticals Enters Into Research Agreement With Inex Pharmaceuticals 129
Alnylam Enters Into Co-Development Agreement With November artis 130
Alnylam Enters Into Agreement With November artis 131
Alnylam Pharmaceuticals Enters Into Collaboration With University Of Georgia 133
Alnylam Enters Into Agreement With Cystic Fibrosis Foundation 134
Alnylam Enters Into Agreement With Medtronic 135
Merck Concludes a New Deal With Alnylam Pharmaceuticals 136
Alnylam Enters Into Agreement With Cenix Bioscience 137
Bio-Rad Laboratories Concludes a New Deal With Alnylam Pharmaceuticals 138
Alnylam Pharmaceuticals Enters Into Licensing Agreement With Inex Pharmaceuticals 139
Alnylam Enters Into Licensing Agreement With Dharmacon 140
Alnylam Enters Into License Agreement With Hybridon 141
Alnylam Pharmaceuticals Enters Into Licensing Agreement With GlaxoSmithKline 142
Tekmira Pharmaceuticals Enters Into Licensing Agreement With Alnylam Pharmaceuticals 143
Alnylam Pharmaceuticals Enters Into Licensing Agreement With Tekmira Pharmaceutical 144
The University of Queensland Enters Into Licensing Agreement With Alnylam Pharmaceuticals 145
Alnylam Pharmaceuticals Enters Into Licensing Agreement With Mount Sinai School 146
Alnylam Pharmaceuticals Enters Into Licensing Agreement With University of Queensland 147
Roche Expands Licensing Agreement With Alnylam 148
Alnylam Enters Into License Agreement With Koken 149
Alnylam Pharmaceuticals Enters Into Licensing Agreement With Isis Pharmaceuticals 150
Alnylam Pharmaceuticals Enters Into Licensing Agreement With Calando Pharmaceuticals 151
Takeda Pharmaceutical Enters Into Collaboration Agreement With Alnylam Pharmaceuticals 152
Alnylam Pharmaceuticals And Tekmira Pharmaceutical Enter Into Licensing Agreement 154
Alnylam Enters Into Agreement With Shanghai GenePharma 155
Alnylam Pharmaceuticals Enter Into Licensing Agreement With GeneDesign 156
Roche Enters Into Licensing Agreement With Alnylam Pharmaceuticals 157
Alnylam Pharmaceuticals Enters Into Licensing Agreement with Hayashi Kasei 159
Alnylam Enters Into Licensing Agreement With Inex Pharmaceuticals 160
Alnylam Pharmaceuticals Enters Into Licensing Agreement With Quark Pharmaceuticals 161
Alnylam Enters Into Agreement With Calando 162
Alnylam Enters Into Agreement With Bioneer 163
Alnylam Enters Into Agreement With Immune Disease Institute 164
Alnylam Enters Into Agreements With Massachusetts Institute of Technology 165
Gen-Probe Enters Into Licensing Agreement With Alnylam Pharmaceuticals 166
Alnylam Pharmaceuticals Enters Into Licensing Agreement With Integrated DNA Technologies 167
Alnylam Pharmaceuticals Enters Into Licensing Agreement With QIAGEN 168
Alnylam And Isis Enter Into License Agreement With Stanford University 169
Alnylam Enters Into License Agreement With MWG Biotech 170
Nastech Pharmaceutical Enters Into Agreement With Alnylam Pharmaceuticals 171
Alnylam Enters Into A Licensing Agreement With Sigma-Aldrich 172
Alnylam Enters Into License Agreement With Eurogentec 173
Alnylam Amends Its Agreements With Max Planck Society 174
Alnylam Enters Into Agreement With Ambion 175
Alnylam Enters Into Agreement With Benitec 176
Alnylam Pharmaceuticals Enters Into Licensing Agreement With GeneCare Research Institute 177
Alnylam And Isis Enter Into Licensing Agreement With Max Planck Society 178
Isis Pharmaceuticals Enters Into Licensing Agreement With Alnylam Pharmaceuticals 179
Alnylam Enters Into License Agreement With RNAX 180
Alnylam Enters Into Licensing Agreement With Invitrogen 181
Alnylam Enters Into Licensing Agreement With Cell Signaling Technology 182
Alnylam Pharmaceuticals Files Registration Statement For Public Offering Of Securities For US$ 150 Mln 183
Alnylam Completes Private Placement Of US$ 1 Mln With November artis 184
Tekmira Completes Private Placement Of US$ 5 Mln With Alnylam 186
Alnylam Pharmaceuticals Completes Private Placement Of US$ 5 Mln 188
Alnylam Pharmaceuticals Completes Public Offering Of US$ 103 Mln 190
Alnylam Completes Public Offering Of US$ 67 Mln 192
Alnylam Pharmaceuticals Completes Private Placement Of US$ 5 Mln 194
Alnylam Pharmaceuticals Completes Initial Public Offering Of US$ 35 Mln 196
List of Figures
Alnylam Pharmaceuticals, Inc – Pipeline by Therapy Area and Indication, H2 2011 13
Alnylam Pharmaceuticals, Inc – Pipeline by Stage of Development, H2 2011 15
Alnylam Pharmaceuticals, Inc – Pipeline By Therapeutic Class, H2 2011 37
Alnylam Pharmaceuticals, Inc - Pipeline By Target, H2 2011 39
Alnylam Pharmaceuticals, Inc – Pipeline By Route of Administration, H2 2011 41
Alnylam Pharmaceuticals, Inc – Pipeline By Molecule Type, H2 2011 42
